Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

Related Keywords

Madrid ,Spain ,Norway ,United Kingdom ,Oslo ,Enriqueta Felip ,Bergenbio Skeie ,Prnewswire Bergenbio ,Martin Olin ,Oddbjorn Straume ,Hebron University Hospital ,Oslo Stock Exchange ,European Society Of Clinical Oncologists ,Haukeland University Hospital In Bergen ,European Society ,Clinical Oncologists ,Annual Meeting ,Thoracic Cancer Unit ,Poster Title ,Monday October ,Board Number ,Assistant Professor ,Clinical Science ,Haukeland University Hospital ,Investigator Led Study ,Presentation Title ,Saturday October ,Leon Auditorium ,Chief Executive Officer ,Non Small Cell Lung Cancer ,Media Relations Jan ,